Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
The full-length 43-amino acid peptide from which TB-500 is derived. Thymosin Beta-4 is the most abundant member of the beta-thymosin family and plays a central role in tissue repair, cell migration, and anti-inflammatory signaling.
A synthetic 15-amino acid peptide derived from a protective protein found in human gastric juice. One of the most widely researched peptides for tissue repair and recovery.
Sequesters G-actin monomers, regulating actin polymerization critical for cell motility and wound healing. Promotes angiogenesis, reduces inflammation via NF-κB modulation, and supports stem cell differentiation. TB-500 is a synthetic fragment of the active region.
BPC-157 promotes angiogenesis (new blood vessel formation), upregulates growth factor expression, and modulates nitric oxide synthesis. It appears to accelerate healing of tendons, ligaments, muscles, and the GI tract through multiple pathways including the FAK-paxillin pathway.
- Tissue repair and wound healing
- Cardiac tissue protection
- Corneal healing
- Anti-inflammatory support
- Hair regrowth
- Tendon and ligament repair
- Gut healing and GI protection
- Muscle injury recovery
- Joint health
- Post-surgical recovery
- Limited human clinical data for injectable form
- Theoretical oncogenesis concerns (promotes cell migration)
- More expensive than TB-500 fragment
- Injection site reactions
- Limited human clinical trial data
- Most research is animal-based
- Potential interactions with blood pressure medications
- Injection site reactions
- Long-term safety profile unknown
No FDA regulatory category for the full-length peptide. TB-500 (the fragment) is pending PCAC review. The full-length Thymosin Beta-4 is available only as a research chemical.
On April 15, 2026, the FDA announced BPC-157 will be removed from the Category 2 'significant safety risks' list effective April 22, 2026. It is now scheduled for formal PCAC (Pharmacy Compounding Advisory Committee) review on July 23, 2026, to determine whether it should be added to the 503A bulk drug substances list. Removal from Category 2 does not authorize compounding — pharmacies should exercise caution until PCAC issues its recommendation. Previously reclassified to Category 1 in February 2026, a step that is now superseded by this more formal process.
PCAC: July 23, 2026
- Thymosin β4 and its role in tissue repair
2012 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.